Mitoxantrone, Cytosine Arabinoside, and VP-16 in 36 Patients with Relapsed and Refractory Acute Myeloid Leukemia
With intensive induction therapy, complete remission can be achieved in 60%-80% of previously untreated adult patients with acute myeloid leukemia (AML) when a combination of cytarabine arabinoside (Ara-C) and daunorubicin is used . However, half of these patients relapse within 12–16 months. Effective cytostatic drugs and combination therapy schemes need to be developed for those patients whose leukemia cells are primary refractory to Ara-C and daunorubicin or become resistant in relapse.
KeywordsAcute Myeloid Leukemia Complete Remission Induction Therapy Acute Leukemia Cytosine Arabinoside
Unable to display preview. Download preview PDF.